Granted Patent
B2
US 12,576,050 · App. 17/286,282 · Granted Mar 17, 2026
Dosage regime
Assignee:
NOVABIOTICS LIMITED
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to use of cysteamine, formulations comprising cysteamine and pharmaceutically acceptable salts of cysteamine in the treatment of cystic fibrosis and conditions associated with cystic fibrosis.
Claims (11)
1 . A method of treating pulmonary exacerbations in cystic fibrosis, the method comprising administering to a patient in need thereof, cysteamine, or a pharmaceutically acceptable salt thereof, bi-daily as two sub-doses to form a total daily dose, wherein each sub-dose is in a range of 400 to 600 mg and the bidaily sub-doses are administered 8-12 hours apart, wherein the patient in need thereof exhibits pulmonary exacerbations in cystic fibrosis and wherein the treating relates to imparting a benefit to patients afflicted with cystic fibrosis or a condition associated with cystic fibrosis.
2 . The method of claim 1 , wherein the total daily dose is in the range: a) 800-1000 mg; or b) 850-950 mg.
3 . The method of claim 1 , wherein the total daily dose is administered in equal divided sub-doses.
4 . The method of claim 1 , wherein the total daily dose is 900 mg administered as two sub-doses of 450 mg each.
5 . The method of claim 1 , wherein bi-daily sub-doses are administered 12 hours apart.
6 . The method of claim 1 , wherein the cysteamine is administered as an oral dose.
7 . The method of claim 6 , wherein the oral dose is: a) a liquid; or b) a solid.
8 . The method of claim 1 , wherein the pharmaceutically acceptable salt is cysteamine bitartrate.
9 . The method of claim 1 , wherein the cysteamine, or a pharmaceutically acceptable salt thereof, is in the form of a composition comprising cysteamine, or a pharmaceutically acceptable salt thereof, and one or more selected from the list of: carriers, excipients, diluents, adjuvants and antimicrobial agents.
10 . The method of claim 1 , wherein the method is provided as an adjunct therapy.
11 . The method of claim 1 , wherein each sub-dose is provided as a single unit dose.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 28, 2021
From: O'NEIL, DEBORAH
To: NOVABIOTICS LIMITED
Reel/Frame 056063/0908 →
Priority Claims (2)
CA CA 3021344
· Oct 17, 2018
· national
EP 18201033
· Oct 17, 2018
· regional
Continuity (2)
Continuation In Part
16163407
· Oct 17, 2018
References Cited (79)
US 5554655A
· Thoene
· 1996
[cited by applicant]
US 5646189A
· Thoene
· 1997
[cited by applicant]
US 8389014B2
· Longo et al.
· 2013
[cited by applicant]
US 8415398B2
· Liang et al.
· 2013
[cited by applicant]
US 9339525B2
· O'Neil
· 2016
[cited by examiner]
US 9364491B2
· O'Neil
· 2016
[cited by examiner]
US 20120129946A1
· Thoene
· 2012
[cited by applicant]
US 20120135969A1
· Weiler et al.
· 2012
[cited by applicant]
US 20160106689A1
· O'Neil
· 2016
[cited by applicant]
US 20160206575A1
· O'Neil
· 2016
[cited by examiner]
US 20170348253A1
· O'Neil et al.
· 2017
[cited by applicant]
US 20230338310A1
· O'Neil et al.
· 2023
[cited by applicant]
CN 105101955A
· 2015
[cited by applicant]
JP 2014515356A
· 2014
[cited by applicant]
KR 20140029372A
· 2014
[cited by applicant]
RU 2013131391A
· 2015
[cited by applicant]
WO 9013538A1
· 1990
[cited by applicant]
WO 2007062272A1
· 2007
[cited by applicant]
WO 2010091124A2
· 2010
[cited by applicant]
WO 2010112848A2
· 2010
[cited by applicant]
WO 2010138419A2
· 2010
[cited by applicant]
WO 2012159103A1
· 2012
[cited by applicant]
WO 2013120086A1
· 2013
[cited by applicant]
WO 2016046523A1
· 2016
[cited by applicant]
WO 2016046524A1
· 2016
[cited by applicant]
WO 2016198842A1
· 2016
[cited by applicant]
WO 2017212239A1
· 2017
[cited by applicant]
Devereaux et al. “Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum”, 2015, EBio…
[cited by examiner]
Procysbi, “Prescribing Information PROCYSBI”, 2015, FDA.gov, pp. 1-19 (Year: 2015).
[cited by examiner]
Devereaux et al. “An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis”, 2016, Clinical Drug Investigation, 36, pp. 605-612 (Year: 2016).
[cited by examiner]
Devereaux et al. , “An open label investigation of the tolerability and pharmacokinetics of oral cysteamine in adults with cystic fibrosis”, 2015, Journal of Cystic Fibrosis, Poster 141 (Year: 2015).
[cited by examiner]
“Cystagon”, 2007, Mylan Pharmaceuticals, pp. 1-13 (Year: 2007).
[cited by examiner]
Jacquot et al. “Hyperinflammation in airways of cystic fibrosis patients: what's new?”, 2008, Expert Review of Molecular Diagnostics, 8, pp. 359-363 (Year: 2008).
[cited by examiner]
Official Action dated Apr. 18, 2023 issued in corresponding European Patent Application No. 19786612.2.
[cited by applicant]
European Search Report, dated Apr. 12, 2019, issued in corresponding European Patent Application No. 18201033.0.
[cited by applicant]
International Search Report/Written Opinion, dated Jan. 9, 2020, issued in corresponding International Application No. PCT/EP2019/078279.
[cited by applicant]
Anonymous: “NovaBiotics Announces New Data on Cysteamine (Nylexa (TM) as an Antimicrobial Resistance Breaker n Multi Drug Resistant Bacteria,” Business Wire, Jun. 18, 2016, pp. 1-3.
[cited by applicant]
Buchan B.E. “Formulation Studies on Cysteamine For The Treatment of Nephropathic Cystinosis” Aug. 1, 2011, [Retrieved on Sep. 6, 2017], pp. 1-223, XP55404192, Retrieved from the Internet: URL: https://core.ac.uk.downloa…
[cited by applicant]
Buchan B.E. “The Formulation and Evaluation of a Dry Powder for Pulmonary Delivery in Cystinosis” Jan. 1, 2010, [Retrieved on Sep. 5, 2017], XP55403968, Retrieved from Internet: URL: https://www.cystinosis.org.uk/wp-con…
[cited by applicant]
Cai et al. “Preparation, Characterization and Pulmonary Pharmacokinetics of a New Inhalable Zanamivir Dry Powder” Drug Delivery, Jun. 11, 2015, 23(6), pp. 1962-1971.
[cited by applicant]
Charrier et al. “Cysteamine (Lynovex®), A Novel Mucoactive Antimicrobial & Antibiofilm Agent for the Treatment of Cystic Fibrosis” Orphanet Journal of Rare Diseases, Nov. 30, 2014, vol. 9(1):189 (11 pages).
[cited by applicant]
Chinese Office Action for Chinese Patent Application No. 2017800353607, mailed Aug. 25, 2021, 30 pages (with English translation).
[cited by applicant]
Chinese Third Office Action for Chinese Patent Application No. 201780035360.7, dated Jan. 30, 2022, 23 pages (with English Translation).
[cited by applicant]
European Examination Report for European Patent Application No. 17735616.9 dated Dec. 16, 2020, 4 pages.
[cited by applicant]
Examination Report for European Patent Application No. 21731565.4 dated Feb. 28, 2024, 5 pages.
[cited by applicant]
Examination Report for Indian Patent Application No. 201817044232, dated Nov. 24, 2020, 6 pages.
[cited by applicant]
Flume P.A et al. “Cystic Fibrosis Pulmonary Guidelines” American Journal of Respiratory and Critical Care Medicine, 2007, vol. 176, pp. 957-969.
[cited by applicant]
Holbrook et al. “The Effect of Cysteamine and Epigallocatechin Gallate on the Inflammatory Phenotype in Cystic Fibrosis,” Pediatric Pulmonology 32nd Annual North American Cystic Fibrosis Conference, Oct. 18-20, 2018, De…
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/GB2017/051637, mailed on Sep. 15, 2017, 13 pages.
[cited by applicant]
International Search Report and Written Opinion for Application PCT/GB2021/051269 dated Aug. 24, 2021 (17 pages).
[cited by applicant]
Japanese Office Action for Japanese Patent Application No. 2018563831, mailed Apr. 19, 2022, 5 pages (with English translation).
[cited by applicant]
Kandeel et al. “Virtual Screening and Repurposing of FDA Approved Drugs Against COVID-19 Main Protease,” Life Sciences, Apr. 3, 2020, 251:1-5.
[cited by applicant]
Keith R.L. “Lung Carcinoma” Merck Manual, 2019, Retrieved from the Internet: URL: https://www.merckmanuals.com/professional, 41 pages.
[cited by applicant]
Khanna et al. “Binding of SARS-COV-2 Spike Protein to ACE2 is Disabled by Thiol-Based Drugs; Evidence from in / itro SARS-COV-2 Infection Studies,” bioRxiv, Dec. 8, 2020, 1-22.
[cited by applicant]
Komar. Application of Pantothenic Acid Drugs in the Treatment of Patients with Viral Hepatitis, vol. 63, No. 11, pp. 58-60 (1991)—see English translated summary on p. 60.
[cited by applicant]
Korean Office Action for Korean Patent Application No. 1020187035476, mailed Sep. 24, 2021, 19 pages (with translation).
[cited by applicant]
Lechuga-Ballesteros D et al. “Trileucine Improves Aerosol Performance and Stability of Spray-Dried Powders for Inhalation” Journal of Pharmaceutical Sciences, Jan. 2008, 97(1):287-302.
[cited by applicant]
Li X et al. “Design, Characterization, and Aerosol Dispersion Performance Modeling of Advanced Spray-Dried Microparticulate/Nanoparticulate Mannitol Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers” Journa…
[cited by applicant]
Lockhart S.P. “Inhaled Thiol and Phosphorothiol Radioprotectors Fail to Protect the Mouse Lung:, Radiotherapy and Oncology” Oct. 1, 1990, 19(2):187-191.
[cited by applicant]
Mcintosh, “NovaBiotics Announces Fast-Track Repurposing of its Experimental Drug Nylexa for COVID-19 Trials and Plans for Earliest Possible Compassionate Use,” Press Release, Apr. 13, 2020.
[cited by applicant]
Mexico Office action for Mexican Application No. MX/a/2018/014278 dated Feb. 18, 2021, 7 pages (English Translation).
[cited by applicant]
Russia Office Action for Russian Patent Application No. 2018142841, dated Feb. 20, 2021, 7 pages (English Translation).
[cited by applicant]
Russia Office Action for Russian Patent Application No. 2018142841, dated Sep. 30, 2020, 15 pages (with English Translation).
[cited by applicant]
United Kingdom Intellectual Property Office Search Report for Application No. GB2007768.1 dated Nov. 13, 2020 (5 pages).
[cited by applicant]
Examination Report dated Jul. 17, 2024 issued in corresponding Australian Patent Application No. 2019360638 (4 pages).
[cited by applicant]
Endeman et al., “Systemic cytokine response in patients with community-acquired pneumonia” 2011, European Respiratory Journal, vol. 37(6), pp. 1431-1438.
[cited by applicant]
Ferrari et al., “Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation” 2017, Cell Death and Disease, vol. 8(e2544), pp. 1-11.
[cited by applicant]
Karim et al., “An Association of Virus Infection with Type 2 Diabetes and Alzheimer's Disease” 2014, CNS & Neurological Disorders—Drug Targets, vol. 13, pp. 429-439.
[cited by applicant]
Mcdonnell et al., “Zinc Ejection as a New Rationale for the Use of Cystamine and Related Disulfide-Containing Antiviral Agents in the Treatment of AIDS” 1997, Journal of Medicinal Chemistry, vol. 40(13), pp. 1969-1976.
[cited by applicant]
Sadikot et al., “Pathogen-Host Interactions in Pseudomonas aeruginosa Pneumonia” 2005, American Journal of Respiratory and Critical Care Medicine, vol. 171, pp. 1209-1223.
[cited by applicant]
Schnur, “Is COVID 19 Fueled by a Cytokine Storm”, Apr. 8, 2020, NursingCenter, pp. 1-6, Retrieved Jul. 30, 2025, from Internet: URL: https://www.nursingcenter.Com/blogs-plus/blogs/blogs-post?identifier=Is-COVID-19-Fuele…
[cited by applicant]
Holbrook et al., “The effect of cysteamine and epigallocatechin gallate on the inflammatory phenotype in cystic fibrosis,” Oct. 2018, Pediatric Pulmonology, 32nd Annual North American Cystic Fibrosis Conference, 3 pages…
[cited by applicant]
Israeli Examination Report for Application No. 298267 dated Dec. 10, 2025, 4 pages.
[cited by applicant]